Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

132.10 -0.26 (-0.20%)
Streaming Delayed Price Updated: 1:06 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Financials ↗
Novartis (NVS) offers a reliable 3.27% dividend yield, backed by strong profitability, a healthy balance sheet, and a history of consistent payouts. 
Via Chartmill
News headline image
Silver Shines as Global Tariff Storm Gathers: A Safe-Haven and Strategic Imperative in 2025
As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Novartis&#39; Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder ↗
Novartis reports Phase 3 results showing that combining ianalumab with eltrombopag significantly extends disease control and improves sustained platelet response in ITP patients. 
Via Benzinga
Novartis Stock Softens Premarket Even As It Raises 2030 Outlook, Sales Guidance For Two Key Cancer Drugs ↗
Via Stocktwits
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗
Via Stocktwits
Topics Workforce
News headline image
Can the Vanguard International High Dividend Yield Index Fund ETF Shares Outperform Again in 2026? ↗
This low-cost international dividend ETF nearly doubled the S&P 500's return in 2025 -- but replicating that performance will require the stars to align once more. 
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
This hot biotech stock could have a lot more room to run. 
Via The Motley Fool
News headline image
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,... 
Via MarketMinute
Topics Artificial Intelligence Death Intellectual Property
News headline image
Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny
New York, NY – December 3, 2025 – In a significant move reverberating through the biotechnology sector, investment banking giant Morgan Stanley has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN)... 
Via MarketMinute
Topics Intellectual Property
News headline image
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗
Janux shares plunged after the JANX007 trial update prompted widespread target cuts, even as retail traders framed the selloff as poised for a rebound. 
Via Stocktwits
News headline image
1 No-Brainer International Vanguard ETF to Buy Right Now for Less Than $100 ↗
A weakening dollar makes this ETF more appealing. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
2 High-Yielding ETFs That Can Bankroll Your Retirement for Years ↗
These funds offer yields that are more than three times the S&P 500 average. 
Via The Motley Fool
Topics ETFs Economy Retirement
News headline image
Why Novartis Stock Topped the Market Today ↗
The company has a brand-new product to ship to pharmacies. 
Via The Motley Fool
News headline image
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults ↗
Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements. 
Via Benzinga
News headline image
Novartis Stock Rises Premarket After FDA Approves First Gene Therapy For Teens And Adults With Muscle-Weakening Disorder ↗
FDA cleared Itvisma as the first gene-replacement therapy available to people 2 and older with the rare muscle-weakening condition. 
Via Stocktwits
News headline image
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Comprehensive Value Investment Analysis ↗
Novartis (NVS) appears undervalued with a low P/E ratio, strong profitability, and solid financial health, making it a compelling stock for value investors. 
Via Chartmill
News headline image
Bionique Wins Dual Golds for “Exosome + Probiotic” Breakthrough in Women’s Microbiome Health
Via Get News
News headline image
European Stocks Soar as Strong Earnings Quell 'AI Bubble' Fears
European equity markets have experienced a significant resurgence around November 20, 2025, with major indices climbing as robust company results, particularly from the technology sector, have... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗
Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030. 
Via Benzinga
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
Via Investor Brand Network
News headline image
Is the Market Bullish or Bearish on Novartis AG? ↗
 
Via Benzinga
News headline image
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗
AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
From BioMedWire
Via GlobeNewswire
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors ↗
Novartis (NVS) offers a strong 3.31% dividend yield with a history of reliable payouts and growth, backed by excellent profitability and financial health. 
Via Chartmill
News headline image
BIOCHINA2026 – Fusion Forward: Uniting the Global Biopharma Community in Suzhou
Via Press Release Distribution Service
News headline image
Trump Unveils $200 Billion Trade Deal With Switzerland And Liechtenstein To Cull $38.5 Billion US Goods Deficit By 2028 ↗
President Donald Trump announced a framework for a trade deal with Switzerland and Liechtenstein on Friday. 
Via Benzinga
Topics Government
News headline image
AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This... 
Via TokenRing AI
Topics Artificial Intelligence Economy Product Recall
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
BIOCHINA2026 – Fusion Forward: Uniting the Global Biopharma Community in Suzhou
Via Get News
News headline image
AI Revolutionizes Cardiovascular Clinical Trials: A Leap Towards Cheaper, Faster Drug Development
San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This... 
Via TokenRing AI
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.